<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00041262</url>
  </required_header>
  <id_info>
    <org_study_id>MRC-OE05</org_study_id>
    <secondary_id>CDR0000069457</secondary_id>
    <secondary_id>EU-20204</secondary_id>
    <nct_id>NCT00041262</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Patients With Esophageal Cancer</brief_title>
  <official_title>A Prospective Randomized Trial Comparing Standard Chemotherapy Followed By Resection Versus Infusional Chemotherapy In Patients With Resectable Adenocarcinoma Of The Oesophagus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells. It is not&#xD;
      yet known which regimen of combination chemotherapy is more effective in treating esophageal&#xD;
      cancer.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to compare the effectiveness of two regimens of&#xD;
      combination chemotherapy in treating patients who are undergoing surgery for esophageal&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare survival and quality of life of patients with resectable adenocarcinoma of the&#xD;
           esophagus treated prior to surgery with standard chemotherapy comprising cisplatin and&#xD;
           fluorouracil versus prolonged infusional chemotherapy comprising cisplatin, epirubicin,&#xD;
           and fluorouracil.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are randomized to one of two&#xD;
      treatment arms.&#xD;
&#xD;
        -  Arm I (Standard chemotherapy): Patients receive cisplatin IV over 4 hours on days 1-4&#xD;
           and fluorouracil IV continuously on days 1-4. Treatment repeats every 21 days for 2&#xD;
           courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Arm II (Infusional chemotherapy): Patients receive cisplatin IV over 4 hours on day 1,&#xD;
           epirubicin IV on day 1, and fluorouracil IV continuously. Treatment repeats every 21&#xD;
           days for 4 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients undergo surgery 4-6 weeks after the last dose of fluorouracil in arm I or anytime&#xD;
      after the fluorouracil infusion is completed in arm II.&#xD;
&#xD;
      Quality of life is assessed at baseline, immediately before starting the last course of&#xD;
      chemotherapy, immediately before surgery, 6 weeks post-operatively, and at 6, 9, 12, 18, and&#xD;
      24 months after randomization.&#xD;
&#xD;
      Patients are followed every 3 months for 1 year, every 6 months for 5 years, and then&#xD;
      annually thereafter.&#xD;
&#xD;
      Peer Reviewed and Funded or Endorsed by Cancer Research UK&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 1,300 patients (650 per treatment arm) will be accrued for&#xD;
      this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2004</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local control</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity from surgery and chemotherapy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">1300</enrollment>
  <condition>Esophageal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the esophagus or type 1 or 2 tumors of the&#xD;
             gastroesophageal junction&#xD;
&#xD;
               -  Stage IIB or greater by spiral or multi-slice CT scan and endoscopic ultrasound&#xD;
&#xD;
               -  Amenable to primary surgery with curative intent&#xD;
&#xD;
          -  No para-aortic/celiac lymphadenopathy greater than 1 cm on CT scan and/or greater than&#xD;
             6 mm on endoscopic ultrasound&#xD;
&#xD;
          -  No disease invading the airways, aorta, pericardium, or lung&#xD;
&#xD;
          -  No liver, lung, or other distant metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  WHO 0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC greater than 3,000/mm3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Liver function tests no greater than 1.5 times normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Glomerular filtration rate greater than 60 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  Ejection fraction greater than 50% OR&#xD;
&#xD;
          -  Normal echocardiograph&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  FEV1 greater than 1.5 L&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  No prior primary malignancy&#xD;
&#xD;
          -  No significant medical condition that would preclude study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Derek Alderson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Derek Alderson, MD</last_name>
      <phone>44-121-627-2276</phone>
      <email>d.alderson@bham.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2007</verification_date>
  <study_first_submitted>July 8, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>August 9, 2013</last_update_submitted>
  <last_update_submitted_qc>August 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2013</last_update_posted>
  <keyword>stage IIB esophageal cancer</keyword>
  <keyword>stage IIIA esophageal cancer</keyword>
  <keyword>stage IIIB esophageal cancer</keyword>
  <keyword>adenocarcinoma of the esophagus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

